Literature DB >> 6587018

Abnormalities of chromosome 16 in association with acute myelomonocytic leukemia and dysplastic bone marrow eosinophils.

D E Hogge, S Misawa, N Z Parsa, A Pollak, J R Testa.   

Abstract

Six patients with M4 acute myelomonocytic leukemia ( AMMoL ) were identified who had abnormalities of chromosome 16 in bone marrow cells. Five had a pericentric inversion, inv(16)( p13q22 ), and a sixth patient had a translocation, t(16;16)(p13.1;q22). Each of these six patients had bone marrow eosinophils that were abnormal in morphology on light and/or electron microscopy and by cytochemical stains. The eosinophils constituted 1%-24% of nucleated marrow cells. Of 61 acute nonlymphocytic leukemia (ANLL) patients, all those with AMMoL and abnormal bone marrow eosinophils had an inv(16) or a t(16;16). One other patient in this group had a rearrangement of chromosome 16 (with a break in the short arm at band p13); however, the ANLL type was M1 and no abnormal eosinophils were present. Four patients with ANLL types other than M4 had an increase in marrow eosinophils; three in whom the eosinophils appeared normal and one with ANLL-M2 and bizarre eosinophils morphologically distinct from those seen in AMMoL . Chromosome pair 16 was normal in the latter four patients. AMMoL with dysplastic bone marrow eosinophils appears to represent a unique clinicopathologic entity associated with several related abnormalities affecting 16q . The morphologic features of both blasts and eosinophils may be more important than the absolute number of eosinophils in the marrow in identifying this group of patients. This may have prognostic importance as five of six patients achieved complete remission with standard antileukemic therapy and are still alive.

Entities:  

Mesh:

Year:  1984        PMID: 6587018     DOI: 10.1200/JCO.1984.2.6.550

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  The promoter of the CD11b gene directs myeloid-specific and developmentally regulated expression.

Authors:  C S Shelley; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  High resolution gene mapping of the human alpha globin locus.

Authors:  R D Nicholls; J A Jonasson; J O McGee; S Patil; V V Ionasescu; D J Weatherall; D R Higgs
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

3.  Identification of cell-specific and developmentally regulated nuclear factors that direct myeloid and lymphoid expression of the CD11a gene.

Authors:  C S Shelley; O C Farokhzad; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

4.  Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

Authors:  Woo Jae Kim; Ross A Okimoto; Louise E Purton; Meagan Goodwin; Sara M Haserlat; Farshid Dayyani; David A Sweetser; Andrea I McClatchey; Olivier A Bernard; A Thomas Look; Daphne W Bell; David T Scadden; Daniel A Haber
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

5.  Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.

Authors:  K V Shepard; R Larson; M M Le Beau; L Leichman; B Levin
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

6.  The human beta 2 integrin CD18 promoter consists of two inverted Ets cis elements.

Authors:  E P Böttinger; C S Shelley; O C Farokhzad; M A Arnaout
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.